IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login
Users Online :2343
Small font sizeDefault font sizeIncrease font size
About Editorial Board Ahead of print Current Issue Archive Search Instructions Announcement Etcetera Contact Advertise
Navigate Here
  »   My Preferences 
  »   Manuscript submission
  »   Back To Article

» Article Access Statistics 

Year : 2021 | Volume:  53 | Issue Number:  3 | Page:  226-228

SHORT COMMUNICATION

Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors
Cure Erkan, Kucuk Adem, Cure Medine Cumhur

Number of times this article was viewed 1775
Number of times this article has been printed  from the site 71
Number of times this article was emailed to others 0
Remarks given by readers [ Read ] 0

 
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow